Background Pulmonary fibrosis (PF) caused by interstitial lung diseases (ILDs) affects up to 0.1% of the global population. There is growing global interest in PF, evident from a nearly threefold ...

BECHTELSVILLE, Pennsylvania (WPVI) -- Most of us take breathing for granted. But with pulmonary fibrosis, patients lose that despite the best medical efforts. That outcome is on the verge of change.

Idiopathic pulmonary fibrosis stands as one of medicine’s most challenging respiratory conditions, gradually transforming healthy lung tissue into stiff, scarred material that severely compromises ...

Researchers at Baylor College of Medicine and collaborating institutions have uncovered a key molecular player that is involved in lung repair and in the development of pulmonary fibrosis, a common ...

Panelists discuss how progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF), though distinct in etiology, share a common trajectory of irreversible lung scarring and functional ...

In patients with CF, pre-transplant PH is associated with improved early post-transplant survival, but with poorer outcomes after 3 years.

What Is Jascayd, and Why Does It Matter? Jascayd (nerandomilast) is a new oral medicine approved to treat idiopathic pulmonary fibrosis (IPF) in adults. IPF is a rare and serious condition that causes ...

Fibrosis of the lungs is often a silent disease until it's too late. By the time patients are diagnosed, the scarring of their lung tissue is already advanced, and current treatments offer little more ...

Idiopathic pulmonary fibrosis (IPF) is a serious lung condition involving scar tissue inside your lungs that makes it hard to breathe. It is a progressive condition, which means that it gets worse ...